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Abstract Autism spectrum disorder (ASD) is a highly
heritable disorder of complex and heterogeneous aetiology.
It is primarily characterized by altered cognitive ability
including impaired language and communication skills and
fundamental deficits in social reciprocity. Despite some
notable successes in neuropsychiatric genetics, overall, the
high heritability of ASD (*90%) remains poorly explained
by common genetic risk variants. However, recent studies
suggest that rare genomic variation, in particular copy
number variation, may account for a significant proportion
of the genetic basis of ASD. We present a large scale
analysis to identify candidate genes which may contain
low-frequency recessive variation contributing to ASD
while taking into account the potential contribution of
population differences to the genetic heterogeneity of ASD.
Our strategy, homozygous haplotype (HH) mapping, aims
to detect homozygous segments of identical haplotype
structure that are shared at a higher frequency amongst
ASD patients compared to parental controls. The analysis
was performed on 1,402 Autism Genome Project trios
genotyped for 1 million single nucleotide polymorphisms
(SNPs). We identified 25 known and 1,218 novel ASD
candidate genes in the discovery analysis including
CADM2, ABHD14A, CHRFAM7A, GRIK2, GRM3,
EPHA3, FGF10, KCND2, PDZK1, IMMP2L and FOXP2.
Furthermore, 10 of the previously reported ASD genes and
300 of the novel candidates identified in the discovery
analysis were replicated in an independent sample of 1,182
trios. Our results demonstrate that regions of HH are sig-
nificantly enriched for previously reported ASD candidate
genes and the observed association is independent of
gene size (odds ratio 2.10). Our findings highlight the
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applicability of HH mapping in complex disorders such as
ASD and offer an alternative approach to the analysis of
genome-wide association data.
Introduction
Extended runs of homozygosity (ROH) have recently been
highlighted as a genomic feature that may be useful to map
recessive disease genes in outbred populations (Hilde-
brandt et al. 2009; Lencz et al. 2007; Yang et al. 2010).
Furthermore, even in complex disorders, we expect to find
an unusually high number of affected individuals to have
the same haplotype in the region surrounding a disease
mutation (Durand et al. 2007; Lesch et al. 2008; Wong
et al. 2002). Therefore, a rare pathogenic variant and sur-
rounding haplotype is often enriched in frequency in a
group of affected individuals compared with the haplotype
frequency in a cohort of unaffected controls (The Interna-
tional HapMap Consortium 2003). We propose that
homozygous haplotypes (HH) that are shared by multiple
affected individuals may be important for the discovery of
recessive disease genes in complex disorders. We have
extended the traditional homozygosity mapping method by
analysing the haplotype within shared ROH regions to
identify homozygous segments of identical haplotype that
are present uniquely or at a higher frequency in ASD
probands compared to parental controls (Fig. 1). Such
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regions are termed risk homozygous haplotypes (rHH). We
postulate that rHH may contain low-frequency recessive
variants that contribute to ASD risk in a subset of ASD
patients.
Allelic and locus heterogeneity are major challenges in
the identification of ASD risk loci (Lamb et al. 2000). In
cases where distinct populations share the same risk allele,
differences in allele frequency and LD structure between
populations may result in the risk allele segregating on
different haplotype backgrounds. Correction for population
substructure in large scale studies minimises the rate of
false positives and dilution of a population-specific signal.
Furthermore, Nothnagel et al. (2010) recently reported that
the distribution of SNP-defined ROHs is highly structured
across European populations and highlighted the impor-
tance of accounting for ancestry when undertaking ROH-
based analyses. Our analysis accounts for population
effects by separating the samples into groups of common
ancestry and applying the HH mapping to each population
group independently. It also involves the use of parental
controls to address variation in low-frequency alleles
across populations (Cardon and Palmer 2003). The genetic
ancestry of the sample set was examined by principal
component analysis (PCA), Hopach clustering (van der
Laan and Pollard 2002) and genetic distance Fst calcula-
tions (Supplementary Material 1, Supplementary Fig. 1 and
2, Supplementary Tables 2 and 3). Ten distinct population
clusters were identified ranging in size from 27 to 289
probands (Fig. 2). Population clusters with a minimum of
50 probands were selected for the discovery analysis
(n = 5). Each cluster was analysed independently by HH
mapping and the genes identified in each population cluster
were then compared. In this manner (taking a gene-centric
approach) it is possible to identify genes that may confer
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risk across different populations regardless of whether the
causal haplotype is population-specific or not.
Subjects and methods
Cohort description
The samples used in the HH analysis were collected as part
of an international consortium, the Autism Genome Project
(AGP). Informed consent was obtained from all partici-
pants. The AGP sample set is a trio based collection,
comprising an affected proband and two parents, grouped
into the three distinct diagnostic classes of autism; strict,
broad and spectrum. Affected individuals were diagnosed
using the Autism Diagnostic Interview-Revised (ADI-R)
and/or the Autism Diagnostic Observation Schedule
(ADOS). A detailed description of the AGP sample set is
provided in Supplementary Material 1 and by Pinto et al.
(2010). Raw genotype data for the ASD trios is deposited at
NCBI dbGAP (accession phs000267.v1.p1). The HH
analysis was performed on trios in the autism spectrum
diagnostic category (n = 2,584 trios). The ASD spectrum
trios were further subdivided into stage 1 and stage 2
collections. In the current study, the 1,402 stage 1 trios
were used for the initial discovery analysis and the 1,182
stage 2 trios were used for the independent replication
study.
Genotyping and quality control
Stage 1 samples were genotyped using the Illumina 1M-
single array while the stage 2 samples were genotyped on a
combination of 1M and 1M-duo chips. The 1M SNP array
Fig. 1 The principles and analytical approach of homozygous haplotype
mapping. a The schematic outlines the principle of homozygous
haplotype (HH) mapping. SNP genotype data is collected on each case
and control. Homozygous and heterozygous SNPs are shown in black and
grey respectively. Firstly, runs of homozygosity (ROH) are identified in
the samples (outlined in purple boxes). The overlapping ROH region
shared by a minimum of three individuals (shown between red dashed
lines) is considered for the HH analysis. The haplotypes within the
overlapping ROH region are identified and a Fisher’s exact test applied to
determine if a particular HH is significantly more common in ASD cases
compared to parental controls. Only the haplotypes of those individuals
who have an ROH in the region in question are considered. In the above
example all four individuals (3 ASD cases and 1 parental control) have an
overlapping ROH. However, the haplotype in the overlapping ROH may
differ. The 3 ASD cases have haplotype A (blue) while the parental
control has haplotype B (red). Haplotype A is shared at a higher
frequency in ASD cases compared to parental controls (apply Fisher’s
test) and is termed a risk homozygous haplotype (rHH). This is an
example of a rHH that is specific to ASD probands; b Flowchart of
homozygous haplotype analysis of ASD cohort. The discovery analysis
was performed on 1,402 AGP trios from the AGP stage 1 collection. The
replication study involved an additional 1,182 AGP trios from the stage 2
collection. The stage 1 and 2 samples were clustered together to (1)
separate stage 1 and 2 individuals into population clusters of similar
ancestry and (2) classify stage 2 individuals into the joint ancestry-
matched population clusters for the stage 2 replication study. The same
rHH mapping strategy was applied to the discovery (stage 1) and
replication (stage 2) data sets independently. The genes located in
homozygous haplotypes significantly more common in ASD cases
compared to parental controls were identified in each analysis. The rHH
candidate genes were then compared for the ancestry-matched groups
that had at least 50 probands in both the discovery and replication sample
sets. To assess the contribution of genomic architecture to the rHH
findings in ASD, the same strategy was applied to two additional disease
data sets; bipolar disorder (BD) and coronary artery disease (CAD). The
location of the rHH in ASD, BD and CAD were compared
Hum Genet (2012) 131:565–579 569
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contains 1,072,820 SNP markers at an average inter-marker
distance of 2.7 kb while the 1M-duo chip contains
1,199,187 SNPs with a mean marker spacing of 1.5 kb. The
1,003,736 SNPs that were genotyped on both the 1M and
1M-duo platforms were considered for the analysis. Pos-
sible gender miscalls were assessed through analysis of
chromosome X genotypes in PLINK (version 1.04)
(http://pngu.mgh.harvard.edu/*purcell/plink/) (Purcell
et al. 2007). Duplicates were identified by calculating
identity by state (IBS) values using PLINK and one sample
from each duplicate pair was removed. After quality con-
trol and filtering for autosomal markers, 887,716 SNPs and
7,719 individuals were retained for analysis (Supplementary
Material 1).
Ancestry analysis
The population structure of the sample set was assessed
through principal component analysis (PCA), Hopach
hierarchical clustering and Fst calculations. PCA was
performed with EIGENSTRAT from EIGENSOFT
(version 3.0) (Price et al. 2006) using 70,175 independent
autosomal SNPs with a minor allele frequency[5% and a
call rate of 100%. Tracy–Widom statistics indicated that
the first eight principal components (PCs) were signifi-
cantly contributing to the population structure of the
sample set. Individuals were assigned to clusters based on
similarity in eigenvalues for the first eight PCs using the
Hopach hybrid hierarchical clustering algorithm available
in the R package (van der Laan and Pollard 2002).
Hierfstat was used to calculate pair-wise Fst metrics for
the clusters using 5,000 SNPs randomly chosen from the
panel of 70,175 SNPs used for PCA (Goudet 2005).
Clusters displaying high similarity (Fst value \ 1 9
10-4) were merged, resulting in 10 population clusters for
the HH analysis (Supplementary Material 1 and Supple-
mentary Table 3).
Homozygous haplotype analysis
Long series of consecutive homozygous SNPS, referred to
as runs of homozygosity (ROHs), were identified in each
sample using the ‘homozyg’ function in PLINK. A
threshold of 100 consecutive homozygous SNPs spanning
at least 1 Mb at a minimum density of 1 SNP/50 kb was
implemented. Using the homozyg-group function in
PLINK, samples (min 3) with overlapping ROHs were
pooled and subdivided into haplotype groups (min 95%
allelic identity). Each haplotype within the overlapping
ROH region is referred to as a homozygous haplotype
(HH). For each overlapping ROH, the frequency of each
HH within cases and controls was evaluated using the
Fisher’s exact test (R script). HH that were significantly
more common in ASD probands compared to parental
controls (p value \ 0.05) were considered rHH (Supple-
mentary Tables 1a–m). All subsequent analysis was limited
to these regions. The rHH regions were annotated using the
Illumina 1M annotation file (Human Genome build 36.1
RefSeq). In cases where rHH were located in intergenic
regions, the nearest centromeric and telomeric gene was
noted.
Inspection of LD structure and copy number variants
Patterns of linkage disequilibrium (LD) within the rHH
were visualised and analysed in Haploview using HapMap
CEU as a reference (Barrett et al. 2005). LD was measured
as r2 values and calculated between each pair of SNPs. The
Tagger algorithm (Haploview) was used to determine the
number of tagging SNPs within each rHH at an r2 threshold
of 0.8. Genes located in rHH comprising\10 tagging SNPs
were noted. For each stage 1 population group, the samples
contributing to significant rHH were inspected for CNV
content as detected by Pinto et al. (2010). If present, rHH
Fig. 2 Genetic ancestry of AGP sample set. Principal component
analysis (PCA) of 2,584 ASD proband samples (discovery stage
1 = 1,402 samples, replication stage 2 = 1,182 samples) was
performed in EIGENSOFT. Tracy–Widom statistics indicated that
the first eight principal components (PCs) were significantly contrib-
uting to the genetic variation of the sample set (Supplementary
Table 2). The Hopach hierarchical clustering algorithm was applied
to eigenvalues (y-axis) from the first eight PCs (x-axis) (van der Laan
and Pollard 2002). In the ‘Pop’ column each sample is coloured
according to the AGP site at which it was collected (see legend).
Hopach clustering, non-parametric bootstrapping and genetic distance
calculations (Supplementary Table 3) identified ten ancestral popu-
lation clusters labelled C1 to C10. The five population clusters with a
minimum of 50 probands (C2–C6) were used in the discovery
analysis (n = 1,019 trios)
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identified as CNVs were removed prior to application of
the Fisher’s exact test.
Replication study
A replication study was undertaken using the AGP follow-
up stage 2 data set (freezes 5–8) which comprises 1,182
ASD trios genotyped on a combination of the Illumina 1M
and 1M-duo platforms. The stage 2 data was cleaned with
the stage 1 samples to ensure that the same markers would
be used in both analyses. The stage 1 and stage 2 probands
were clustered to identify ancestry-matched replication
groups. The four population clusters (C3–C6) with C50
probands in both stage 1 and 2 analyses were considered
for the replication study. The same HH mapping method
was applied to the four stage 2 population clusters. The
rHH genes identified in the discovery (stage 1) and repli-
cation (stage 2) analyses were then compared to identify
overlap.
Statistical analyses
Comparison of ROH burden
For each population group, the number and length of
autosomal ROH in ASD probands and parental controls
was compared using a paired t test. ASD probands were
compared to their mothers and fathers separately.
Identification of HHs that are more prevalent in ASD
A Fisher’s exact test was used to identify HH that
were more prevalent in ASD probands compared to
parental controls at a 5% Fisher’s significance level.
As we are assuming a recessive model a one-sided test
was used.
Comparison of results across the five stage 1 population
groups
Each of the five population clusters were analysed inde-
pendently and the rHH genes subsequently compared to
identify overlaps. A gene was considered a candidate in
multiple population clusters regardless of whether the
position of the rHH in each population differed (to allow
for population-specific effects). In this manner, it is pos-
sible to identify genes that may confer susceptibility to
ASD across multiple populations even though the under-
lying risk allele may be population-specific. Genes located
in/near rHH over-represented in ASD probands in at least
two population groups were noted.
Enrichment for previously reported ASD genes
A v2 test with Yates’ correction factor was used to deter-
mine if the rHH genes displayed enrichment for previously
reported ASD candidate genes (n = 202). To account for a
potential bias towards large genes, a logistic multiple
regression was performed in STATA including both ASD
gene status and gene size (as defined in UCSC hg18) as
covariates. Thus, if rHH genes were primarily associated
with larger genes, and this was merely a confounding factor
arising simply because of a preponderance of larger genes
in the ASD list of genes (mean length of 185 kb compared
to 57 kb for other genes), then the multiple regression
model would identify gene size as the significant predictor,
and fail to identify ASD genes as being significantly over-
represented amongst the rHH genes.
Results
Identification of risk homozygous haplotypes
Runs of homozygosity (ROH) of at least 1 Mb and 100 SNPs
were identified in samples from each of the five population
clusters using PLINK (‘‘Subjects and methods’’ and Sup-
plementary Material 1). A paired t test demonstrated that
ASD probands did not have a higher genome-wide burden of
ROH compared to parental controls (Supplementary Fig. 3).
The findings from the current ASD study reflect those of a
related neuropsychiatric condition, bipolar disorder, where it
was recently reported that individuals with bipolar disorder
do not have an excess of runs of homozygosity (Vine et al.
2009). A one-sided Fisher’s exact test was applied to identify
HH that were more prevalent in ASD probands compared to
parental controls at a 5% significance threshold. Such HH are
considered regions of interest and are referred to as rHH.
Since low-frequency variants will rarely be present at a high
enough frequency to survive multiple testing, they will not be
detected with the correction methods currently available.
Therefore unless otherwise stated, p values have not been
corrected for multiple testing. Genes located within or
overlapping the rHH were noted. In cases where the rHH was
intergenic, the neighbouring centromeric and telomeric genes
were used. We found that, on average, 76% of the rHH were
genic (Supplementary Fig. 4).
Haplotype sharing in homozygous segments
To determine if excess HH sharing is also likely to occur in
a non-disease cohort we compared the number of HHs that
are more common in ASD probands compared to parental
controls and the number of HHs that are more common in
parental controls compared to ASD cases. We observed
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that ASD probands shared a significantly higher number of
homozygous segments of identical haplotype compared to
the parental control group (paired t test p value = 0.008)
(Fig. 3). This finding suggests that, although ASD pro-
bands may not have a higher burden of homozygous seg-
ments compared to parental controls, the probands display
a much higher degree of haplotype sharing within
overlapping homozygous regions. Excess haplotype shar-
ing often indicates the presence of a disease locus (Bahlo
et al. 2006), an observation that forms the basis of the
current study. Two distinct types of rHH were identified in
the affected cohort; (1) homozygous segments with a
haplotype that is present in ASD probands but absent in
parental controls and (2) homozygous segments with a
Fig. 3 Comparison of HH sharing in ASD cases and parental
controls. The normalised number of rHH (HH that are more common
in one group compared to the other) in five population clusters with a
minimum of 50 probands. The dark grey bars represent the number of
HH that are more common (Fisher’s exact test right p value\0.05) in
ASD probands compared to parental controls. Such regions are
referred to as rHH throughout the paper. The light grey bars denote
the number of HH that are more common (Fisher’s exact test left
p value \0.05) in parental controls compared to ASD probands. To
account for differences in sample size, counts have been normalised
to a group of 100 samples (Supplementary Material 1). The number of
rHH identified in ASD probands is significantly greater than the
number of rHH identified in parental controls across the five
population clusters (paired t test p value = 0.008)
Table 1 Summary of rHH results for each population cluster
Cluster No. of ASD probands No. of parental controls Significant rHH Total no. of rHH genes
Total ASD-specific Enriched
C2 148 294 40 23 17 243
C3 289 584 99 44 55 341
C4 85 170 11 5 6 79
C5 280 560 100 48 52 417
C6 217 434 57 18 39 372
Total 1,019 2,024 307 138 169 1,452a
A summary of results for each of the ancestry-matched population clusters in the discovery analysis. The number of homozygous haplotypes
over-represented [5% significance level, risk homozygous haplotypes (rHH)] in the ASD cohort is further subdivided into ASD-specific (only
present in probands) and enriched (more common in probands than controls). The number of genes implicated by the rHH in each population
cluster is shown in the final column. A total of 307 rHH were identified across the 5 population clusters. These regions contained or were adjacent
to 1,452 genes
a When genes that are found in more than one population cluster are considered only once, the final number of genes is 1,243
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haplotype that is present at a higher frequency in ASD
cases compared to parental controls. A summary of the
rHH results is shown in Table 1. The average rHH size
across the five population clusters was 541.27 kb, 24-fold
larger than the average haplotype block (Gabriel et al.
2002). Visual inspection of LD structure showed that the
rHH extended across multiple LD blocks and 90% of rHH
contained at least 10 tagging SNPs, indicating that it is
unlikely that the observed HH sharing is a consequence of
long-range LD.
Genes located in rHH across multiple population
clusters
We identified 192 genes (1 gene in 4 populations, 15 in 3
populations and 176 in 2 populations) that are in or near
rHH regions significantly more prevalent among the ASD
probands in two or more population clusters (Supplemen-
tary Table 4). In four of the five population clusters, an
rHH was found in an evolutionary-conserved intergenic
region on 3p12.1 in the vicinity of CADM2, a novel ASD
candidate gene (Fig. 4). The rHH adjacent to CADM2 were
identified in 23/1,019 ASD cases and 11/2,031 parental
controls [Yates’ corrected v2 p = 1.9 9 10-5, OR = 4.26
(2.1, 8.6)]. Recent studies have highlighted the presence of
long-range regulatory mutations in several diseases and
suggest that cis-regulatory domains of developmental
genes may extend over megabases of DNA flanking its
coding sequences (Benko et al. 2009; Kleinjan and van
Heyningen 2005). CADM2 is a member of the synaptic cell
adhesion molecule (SynCAM) immunoglobulin superfam-
ily which has potential roles in early postnatal development
of the central nervous system (specifically synapse for-
mation) and is predominantly expressed in neurons of the
developing and adult brain (Thomas et al. 2008). The
encoded protein localises to both excitatory and inhibitory
neurons which is intriguing given that there is compelling
evidence for dysfunction in neuronal communication and
excitatory/inhibitory imbalance in autism (Persico and
Bourgeron 2006; Sudhof 2008). Of interest, CADM2 con-
tains a neurexin domain. Rare variation contributing to
autism has previously been identified in neurexin and
neurexin-binding genes (Arking et al. 2008; Betancur et al.
2009; Kim et al. 2008). In our study, the location of the
rHH in relation to CADM2 differed between each of the
four population clusters. This may indicate population-
specific risk loci arising from different founder events
involving the gene or a control element proximal to the
Fig. 4 rHH identified in four population clusters in the vicinity of
CADM2. An rHH located in a non-coding evolutionary-conserved
region on 3p12.1 was identified in four of the five population clusters.
The coloured bars represent the run of homozygosity in each patient/
parental control carrying the rHH. For each population cluster, the rHH
is the shared ROH segment. The ROH profile is presented with a
conservation plot (ECR browser; conservation throughout mouse, dog
and rhesus monkey of fragments[350 bp at 75% identity indicated in
red). rHH adjacent to CADM2 were identified in 23/1019 ASD cases and
11/2031 parental controls [Yates’ corrected v2 p value = 1.9 9 10-5,
OR = 4.26 (2.1, 8.6)]
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gene. Given the recent implication of synaptic genes in
ASD susceptibility (Durand et al. 2008; Zoghbi 2003) and
the strong functional candidacy of CADM2, its involve-
ment in ASD warrants further investigation.
Other novel ASD candidate genes located in rHH across
multiple population clusters include GRIK2; an ionotropic
glutamate receptor associated with autosomal recessive
mental retardation and autism (Jamain et al. 2002; Mota-
zacker et al. 2007), GRM3; a metabotropic glutamate
receptor that impacts on aspects of cognition dependent on
hippocampal and prefrontal cortical function (Egan et al.
2004), EPHA3; an ephrin receptor involved in axon guid-
ance and synaptic plasticity, FGF10; a fibroblast growth
factor involved in regulating the onset of neurogenesis and
cortical brain size (Sahara and O’Leary 2009), ABHD14A;
a cerebellar abhydrolase protein with a role in granule
neuron development (Hoshino et al. 2003), NTS; a brain
and gastrointestinal peptide involved in passive avoidance
behaviour and the modulation of dopaminergic neuro-
transmission and serotonin levels (Shugalev et al. 2008),
SCAMP5; a brain-enriched membrane trafficking protein
located 10 kb centromeric to the breakpoint of a 15q de
novo balanced translocation in a patient with autism
(Castermans et al. 2010), CHRFAM7A; a hybrid gene
involving a partial duplication of the alpha7 nicotinic
acetylcholine receptor in the postsynaptic membrane and
that has previously been associated with schizophrenia,
bipolar disorder, dementia, Alzheimer’s disease and
attention-deficit hyperactivity disorder and KCND2; a
brain-specific voltage-gated ion channel component that
regulates neurotransmitter release and neuronal excitability
at the glutamatergic synapse where SHANK3 and NLGN
products are formed.
ASD-specific rHH across multiple populations
Of particular interest in this study are the rHH that are
ASD-specific; shared by multiple ASD patients but not
present in any of the parental controls. We identified
8 ASD-specific rHH, implicating 12 genes (POLR3C,
CD160, ZNF364, PDZK1, NUDT17, GBE1, HTR1E,
C10orf95, CUECDC2, CHORDC1, MGAT4C and
C12orf50) and a cluster of defensins (8p23.1), which are
significant in at least two population clusters. The ASD-
specific rHH at 1q21.1 is shared by three population clus-
ters and the maximal overlapping region contains a single
gene; PDZK1. PDZK1 encodes a scaffold protein that
connects plasma membrane proteins and regulatory com-
ponents. The PDZK1 protein is part of a complex that
includes SYNGAP1, KLHL17 and NMDA receptors and
this complex is important for maintaining the integrity of
actin cytoskeleton structures in neurons (Chen and Li
2005). In addition, the ASD-specific rHH at 1q21.1
overlaps with a rare deletion associated with schizophrenia
in two independent studies (Tam et al. 2009). Furthermore,
we observed that 8 of 996 ASD cases from the AGP sample
set analysed for rare copy number variants in the study by
Pinto and colleagues have a rare duplication (n = 6;
145–1,470 kb) or deletion (n = 2; 189 and 528 kb)
involving the PDZK1 gene.
Enrichment for genes previously implicated in ASD
The genes located in rHH regions were compared to
autosomal genes that have previously been implicated in
ASD in association studies, expression analyses and chro-
mosomal anomaly studies, as reviewed by Yang and Gill
(2007). We extended the literature search to 2009 using the
same search criteria provided by Yang and Gill (Supple-
mentary Table 5). Of the 1,243 genes identified in the
study, 25 are published ASD candidate genes (Table 2).
However, considerable caution is required in interpreting
such findings, since both rHH genes and previously
reported ASD candidate genes tend to be larger (p \ 10-3).
Accordingly, we performed a logistic multiple regression
including both ASD gene status and gene size as covari-
ates. While the odds ratio decreased slightly, it remained
highly significant, indicating that there is an association
between rHH status and ASD status that is independent of
gene size [size adjusted p = 0.001, OR = 2.10, (1.36,
3.25)]. In addition, 9 ASD candidates (BTN2A1, FOXP2,
GBE1, GRIK2, IMMP2L, LRFN5, LRRN3, ROBO1 and
SLC4A10) are amongst the 192 genes located in rHH in
two or more population clusters [size adjusted
p = 6.9 9 10-5, OR = 4.76 (2.34, 9.64)].
Replication study
To investigate our findings further, we performed a repli-
cation study on an additional 1,182 independent AGP trios.
The replication cohort (stage 2) was clustered with the
discovery sample set (stage 1) to identify ancestry-matched
replication groups (Supplementary Material 1). The four
population clusters (C3–C6) with at least 50 probands in
both the discovery and replication sample sets were con-
sidered for the replication study (Supplementary Table 6).
The same analytical strategy was applied to the replication
sample set and identified 1,190 genes in rHH regions. The
rHH genes identified in the discovery (number of
genes = 1,086) and replication (number of genes = 1,190)
analyses of population clusters C3–C6 were subsequently
compared. We found that 28.5% (310/1086 genes) of the
rHH genes identified in the discovery analysis occurred in a
rHH in at least one of the replication population clusters
(Supplementary Table 7). In particular, the replication
study provided further evidence for the possible
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involvement of the novel candidate genes ABHD14A,
CADM2, EPHA3, FGF10, GRIK2, GRM3, and KCND2.
SCAMP5 and CHRFAM7A (found in rHH in multiple popu-
lation clusters in the discovery analysis) did not replicate in
their corresponding replication clusters while NTS was sig-
nificant in one of two ancestry-matched replication groups.
Furthermore, 10 previously identified ASD candidate genes
(ALAS1, CSMD3, FOXP2, GABRG1, GBE1, GRM8,
FBXO33, IMMP2L, SLC4A10 and ACO2) were located in
rHH regions in both the discovery and replication HH map-
ping analyses [size adjusted p = 0.001, OR = 2.99 (1.50,
5.90)]. The ASD-specific rHH at 1p21.1 was also significant in
two of four population clusters in the replication study pro-
viding further evidence of an ASD risk gene at this locus.
rHH located in significant ASD linkage peaks
The rHH regions identified in the discovery (stage 1) and
replication (stage 2) analyses were compared to the geno-
mic regions that have previously displayed significant
linkage (LOD score [3.3) with ASD. We found that 31
rHH identified in the discovery and replication analyses are
located under significant ASD linkage peaks (Supplemen-
tary Table 8). Of interest, three of the ASD linkage peaks
harbour rHH from multiple population groups.
Firstly, three population groups in the replication anal-
ysis (stage 2: C4, C5, C6) have an overlapping rHH within
the 7q22.1 ASD linkage peak (International Molecular
Genetic Study of Autism Consortium (IMGSAC) 2001).
The rHH at 7q22.1 range in size from 545 to 808 kb. The
maximal shared region is 545.3 kb and includes 19 genes.
Three of the genes at this locus (CYP3A4, CYP3A5 and
CYP3A7) are members of the cytochrome P450 super-
family that plays important roles in hormone synthesis and
breakdown, cholesterol synthesis, vitamin D metabolism
and the metabolism of drugs and toxic compounds. Data
from the KEGG databases suggests that members of the
cytochrome P450 family such as CYP3A4 and CYP3A5 are
involved in 5-HT (serotonin) catabolism (Jia et al. 2004).
Moreover, in the brain, mRNA expression appears to be
specific to neurons in the cerebral cortex and basal ganglia,
regions of the brain that are consistently implicated in ASD
(Dutheil et al. 2008). In addition, genetic polymorphisms of
cytochrome P450 enzymes have been linked to ASD and
schizophrenia (Currenti 2010).
Secondly, a rHH shared by two populations in the dis-
covery analysis is located within the significant ASD
linkage peak at 15q13.1–q14 (Lauritsen et al. 2006; Liu
et al. 2008; Philippe et al. 1999). This particular locus has
been implicated in several neuropsychiatric disorders. The
overlapping rHH region identified in the current study is
579 kb and contains five genes, only two of which are
coding (CHRFAM7A and ARHGAP11B). Of most rele-
vance to ASD is CHRFAM7A which represents a fusion
product involving a partial duplication of the alpha7 nic-
otinic acetylcholine receptor in the postsynaptic membrane
Table 2 Previously identified ASD candidate genes located in rHH
Pop. No. genes identified
in rHH regions
No. rHH genes previously
implicated in ASD
ASD candidate genes located in rHH regions
Discovery stage 1
C2 243 7 BTN2A1, CSMD3, FNTA, FOXP2, GABRA2, GABRG1, GBE1
C3 341 12 ALAS1, FBXO33, GBE1, IMMP2L, LRFN5, LRRN3, NRXN1,
PRCP, PTGS2, REEP3, ROBO1, SLC4A10
C4 79 – –
C5 417 5 ACO2, FOXP2, GRIK2, HERC2, TSPAN12
C6 372 11 BTN2A1, DOCK4, GBE1, GRIK2, GRM8, IMMP2L, LRFN5, LRRN3,
ROBO1, SLC4A10, WDR75
Replication stage 2
C3 529 8 ALAS1, FOXP2, GBE1, GRIK2, GRM8, IMMP2L, SLC4A10, STOM
C4 70 1 CSMD3
C5 731 9 ACO2, CSMD3, FBXO33, GABRG1, GRM8, NAGLU, PCDH10,
SEPHS2, SLC6A4
C6 46 – –
A number of genes that have previously been implicated in ASD were found to be located in rHH regions in both the discovery and replication
HH mapping studies. In the discovery analysis, 25 previously reported ASD candidate genes occurred in rHH regions. Nine ASD candidate genes
were located in rHH in more than one population group and are shown in bold. Another 16 ASD candidates were located in rHH in a single
population group and may represent population-specific susceptibility genes. We also found that 16 previously implicated ASD genes were
located in rHH regions in the replication study. Two ASD candidate genes were located in rHH in more than one population group and 14 ASD
genes were population-specific. Ten ASD candidate genes (ALAS1, CSMD3, FOXP2, GABRG1, GBE1, GRM8, FBXO33, IMMP2L, SLC4A10
and ACO2) occurred in rHH regions in both the discovery and replication HH mapping analyses
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and a gene from the family with sequence similarity 7.
CHRFAM7A has previously been associated with schizo-
phrenia, bipolar disorder, dementia, Alzheimer’s and
attention-deficit hyperactivity disorder (Feher et al. 2009;
Flomen et al. 2006; Manchia et al. 2010; Martin et al. 2007;
Sinkus et al. 2009). This is the first implication of CHR-
FAM7A in ASD.
Thirdly, we noted a rHH at 20q11.21–q13.12 that was
significantly more common in ASD patients compared to
parental controls in two population groups in the replica-
tion study. The shared rHH region includes 11 genes. The
strongest functional candidate at this locus is MYH7B
which encodes a myosin heavy chain protein that maintains
excitatory synaptic function. Reduction of MyH7B in rats
causes a profound alteration in dendritic spine structure and
excitatory synaptic strength (Rubio et al. 2011). The
resulting abnormal spine phenotype was strikingly similar
to the morphological changes induced by over-expression
of SynGAP1, a gene linked to mental retardation and ASD
(Hamdan et al. 2009; Pinto et al. 2010). The advantage of
the rHH analysis is that the ASD-specific rHH regions are
much smaller (*0.53 Mb) than ASD linkage regions
which range from 2 to 242 Mb and may facilitate identi-
fication of the causative gene within these loci.
Discussion
Despite some notable successes in neuropsychiatric
genetics, overall the high heritability of ASD (*90%)
remains poorly explained by common genetic risk variants.
Instead, early studies of rare variation, in particular copy
number variation, have suggested that rare variants may
account for a significant proportion of the genetic basis of
ASD. The study of excess haplotype sharing within
homozygous regions offers a complimentary approach to
the analysis of GWAS data in the study of complex disease
and particularly focuses on the contribution of low-
frequency variation to disease risk. We report the first gen-
ome-wide rHH mapping study to identify novel recessive
candidate genes and loci involved in ASD susceptibility.
The strategy was applied to one of the largest ASD trio
collections, subdivided into 10 distinct population clusters.
We identified 307 rHH regions containing 1,243 genes for
further investigation. In cases where ancestry-matched
replication groups were available, almost one-third of the
discovery phase rHH genes (310/1,086) were located in
homozygous haplotypes that were significantly more
common in ASD patients compared to parental controls in
the replication analysis. Importantly, we identified novel
ASD genes that merit further study including ABHD14A,
CADM2, CHRFAM7A, EPHA3, FGF10, GRIK2, GRM3,
KCND2 and PDZK1. The current study also provides
further support for 25 previously reported ASD genes.
Interestingly 192 of the rHH genes were significant in
multiple population clusters. The variation in haplotype of
the rHH across the different populations may suggest the
existence of common risk genes but population-specific
risk alleles. The findings of the current study serve as a
starting point to screen for causal variants and elucidate the
underlying pathogenesis of ASD. In particular, sequence
analysis will be more economically feasible since the
search for causal variants is limited to 1,243 genes and
specifically identifies the patients carrying the rHH of
interest, allowing a more targeted follow-up approach.
Sample size as a limiting factor
Sample size is an important feature of the HH mapping
approach and is a limiting factor in the current study. A
number of the population clusters in the ASD study are of
modest sample size (n \ 100) and five population clusters
could not be included because of insufficient sample
numbers. Larger collections of genetically homogenous
samples would increase the power to detect low-frequency
events. Similarly, due to the small sample sizes, we have
not corrected for multiple testing. The HH sharing strategy
aims to identify genes that may contain low-frequency
disease variants. Given the small sample sizes, such events
are highly unlikely to survive correction for multiple test-
ing. Although this may be considered a weakness it is
important to note that correcting for multiple testing will
not change the relative order of the rHH results (Zaykin
and Zhivotovsky 2005). The distributions of ranks will
remain the same with HHs that show the greatest difference
in frequency between ASD cases and parental controls
remaining as the most important findings. We acknowledge
that by not correcting for multiple testing, there is an
increased risk of false positive findings. To address this we
have focused on the genes that occur in rHH in multiple
population clusters and replicate in the stage 2 sample set,
as they are less likely to be false positives.
Genomic structure underlying rHH regions
Analysis of Log R ratios and B allele frequencies con-
firmed that the rHH regions are not attributed to copy
number deletions. To ascertain whether some unknown
genomic architecture contributed to the observed rHH
findings and also to reduce the risk of false positives, we
undertook rHH mapping in two additional disease data sets
from the Wellcome-Trust Case–Control Consortium;
bipolar disorder (BD) (cases = 1,875 and controls =
2,954) and coronary artery disease (CAD) (cases = 1,963
and controls = 2,978). We hypothesised that genome
architecture could possibly be contributing to the results of
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the ASD rHH analysis if (1) the rHH in the BD and CAD
studies showed a significant overlap with the rHH identi-
fied in the current ASD study and (2) the BD and CAD
rHH genes showed a significant enrichment for previously
identified ASD genes. There was a 2 and 2.6% overlap
between BD-ASD and CAD-ASD rHH regions, respec-
tively, neither of which are greater than expected by chance
(J.P.C., unpublished data). Furthermore the BD and CAD
rHH genes did not display an enrichment for known
ASD candidate genes (BD Yates’ corrected v2 p = 0.815,
CAD Yates’ corrected v2 p = 1.000) suggesting that the
rHH identified in the current study are more likely to be
related to the ASD phenotype than to the genomic archi-
tecture in the rHH regions.
Homozygous haplotype sharing in complex disorders
There are very few analytical strategies designed to iden-
tify rare recessive disease genes for complex traits. The
homozygous haplotype sharing strategy addresses this
issue and proposes a novel concept for searching for genes
that may contain low-frequency disease variants. The most
important feature of the HH mapping approach presented
in this study is the concept; analysis of the haplotype within
shared homozygous segments provides an additional level
of information that has been overlooked in ROH-based
analyses and excess sharing of a homozygous haplotype
amongst patients may support the presence of a rare
recessive disease mutation in the region. In the future, the
strategy itself will undoubtedly benefit from further mod-
ifications and improvements, particularly in the areas of
modelling, simulation and statistics for rare genetic events.
We applied the HH mapping approach to one of the
largest international ASD cohorts (4,206 samples) and
identified novel and known ASD candidate genes which
were replicated in an independent sample set. We also
found that homozygous haplotypes over-represented in
ASD patients were significantly enriched for previously
identified ASD candidate genes, further validating our
approach. Although HH mapping does not identify causa-
tive alleles, the regions reported in the current study pro-
vide narrow genomic intervals containing highly plausible
candidate genes for further investigation. The findings
reported in this study suggest that the analysis of homo-
zygous haplotype sharing may be an important tool in
uncovering some of the missing heritability in a variety of
complex disorders.
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